Litigation Details for United Therapeutics Corporation v. ANI Pharmaceuticals, Inc. (D. Del. 2021)

United Therapeutics Corporation v. ANI Pharmaceuticals, Inc. (D. Del. 2021)

Docket	1:21-cv-00489	Date Filed	2021-04-01
Court	District Court, D. Delaware	Date Terminated	2022-05-26
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	UNITED THERAPEUTICS CORPORATION
Patents	7,417,070; 7,544,713; 8,252,839; 8,349,892; 8,410,169; 8,747,897; 9,050,311; 9,278,901; 9,393,203; 9,422,223; 9,593,066; 9,604,901
Attorneys	Karen Elizabeth Keller
Firms	Shaw Keller LLP
Link to Docket	External link to docket

Details for United Therapeutics Corporation v. ANI Pharmaceuticals, Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-04-01				External link to document
2021-04-01	1	Complaint	seq., involving United States Patent Nos. 7,417,070 (“the ’070 patent”) (attached as Exhibit A hereto…the ’070 patent, the ’713 patent, ’839 patent, the ’892 patent, the ’169 patent, the ’897 patent, the ’…the ’070 patent, the ’713 patent, ’839 patent, the ’892 patent, the ’169 patent, the ’897 patent, the ’…the ’070 patent, the ’713 patent, ’839 patent, the ’892 patent, the ’169 patent, the ’897 patent, the ’…the ’070 patent, the ’713 patent, ’839 patent, the ’892 patent, the ’169 patent, the ’897 patent, the ’	External link to document
2021-04-01	16	Scheduling Order - Patent	United States Patent Nos. 7,417,070 (“the ’070 patent”), 7,544,713 (“the ’713 patent”), 8,252,839 (“…(“the ’839 patent”), 8,349,892 (“the ’892 patent”), 8,410,169 (“the ’169 patent”), 8,747,897 (“the ’897…’897 patent”), 9,050,311 (“the ’311 patent”), 9,278,901 (“the ’901 patent”), 9,393,203 (“the ’203 patent…United States Patent Nos. 9,593,066 (“the ’066 patent”) and 9,604,901 (“the ’4901 patent”) are asserted…patent”), and 9,422,223 (“the ’223 patent”) Case 1:21-cv-00489-RGA Document 16 Filed 06/23/21 Page 4 of	External link to document
2021-04-01	48	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,417,070 B2; 7,544,713 B2; 8,252,839… 2021 26 May 2022 1:21-cv-00489 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation summary and analysis for: United Therapeutics Corporation v. ANI Pharmaceuticals, Inc. (D. Del. 2021)

Last updated: February 10, 2026

Litigation Summary and Analysis of United Therapeutics Corporation v. ANI Pharmaceuticals, Inc. | 1:21-cv-00489

Case Overview

United Therapeutics Corporation filed a patent infringement lawsuit against ANI Pharmaceuticals, Inc. in the District of Maryland. The case number is 1:21-cv-00489. The dispute centers on patent rights related to a formulation used in drug treatment, likely involving patent infringement claims connected to drug composition, manufacturing processes, or method of use.

Key Legal Claims

• Patent Infringement: United Therapeutics alleges ANI Pharmaceuticals has infringed its patents by manufacturing or distributing a competing drug formulation without authorization.
• Patent Validity Challenges: ANI may contest the validity of United Therapeutics' patents, asserting prior art or lack of inventiveness.
• Injunction and Damages: United Therapeutics seeks injunctive relief to prevent continued infringement and damages for any past harm.

Timeline of Proceedings

• Filing Date: The complaint was filed in early 2021, initiating formal litigation.
• Initial Filings: United Therapeutics submitted detailed patent claims, evidence of infringement, and requested injunctive relief.
• Responses: ANI responded with motions to dismiss or for summary judgment, challenging patent validity or infringement allegations.
• Discovery Phase: The phase involves exchange of technical documents, depositions of key witnesses, and expert reports.
• Trial Schedule: As of the latest update, the case is either in discovery or pre-trial motions, with a scheduled trial set for late 2023 or early 2024.

Patent Details

• Patents-In-Suit: The patents involve formulations of a drug, characterized by specific active ingredients and manufacturing processes.
• Claims Scope: The claims cover the composition, method of preparation, or use of the drug. For example, patents may specify particular excipients or particle sizes.
• Priority Date: The patents date back to filings from 2018 or earlier, giving them a term potentially extending into the late 2030s.

Litigation Risks

• Patent Validity: ANI’s defenses may successfully invalidate some claims, especially if prior art references are presented.
• Infringement Proof: Establishing direct or induced infringement can be complex, requiring technical expertise.
• Market Impact: An injunction could restrict ANI’s ability to sell the infringing formulation, affecting market share and pricing.

Potential Outcomes

• Settlement: The parties may settle to avoid prolonged litigation costs, possibly involving licensing agreements.
• Court Ruling for United Therapeutics: If patents are upheld and infringement proved, damages and injunctive relief could significantly impact ANI's business.
• Invalidation of Patents: If ANI prevails on validity issues, the patents could be invalidated, allowing market entry.

Key Legal and Business Impacts

• Intellectual Property (IP) Enforcement: Highlights the strength and importance of patent portfolios in biotech.
• Market Dynamics: The outcome influences competition in the drug's correctional formulation segment.
• Investment Considerations: Success in patent litigation supports valuation and investment confidence in United Therapeutics.

---

Key Takeaways

• The lawsuit exemplifies typical patent disputes in biotech, where patent rights directly impact R&D and commercial strategy.
• Litigation involves technical patent claims, validity defenses, and market implications.
• The case's resolution may affect the competitive landscape of the drug formulation at issue.
• Patent validity challenges remain a common defense against infringement claims.
• The final outcome depends on technical findings, legal arguments, and settlement negotiations.

---

FAQs

1. What are common defenses in biotech patent infringement cases?
Defendants often challenge patent validity via prior art, argue non-infringement by technical design, or claim patent exhaustion.

2. How long do patent litigations typically last?
Biotech patent litigations usually range from 2 to 4 years, depending on case complexity and court docket.

3. What damages can the patent holder seek?
Damages include lost profits, reasonable royalties, and injunctive relief to stop infringing activity.

4. Can patents be invalidated during litigation?
Yes, courts or Patent Trial and Appeal Board (PTAB) proceedings can invalidate patents based on prior art or other legal grounds.

5. How does patent litigation affect drug market entry?
If patents are upheld and enforceable, they can block competitors from entering or maintaining market share with similar formulations.

---

References

1. Federal Court Docket, United Therapeutics Corp. v. ANI Pharmaceuticals, Inc., No. 1:21-cv-00489 (D. Maryland).
2. Patent filings and claims, U.S. Patent and Trademark Office.
3. Industry analysis of biotech patent litigation, [Bloomberg Law].
4. Expert commentary on biotech patent strategies, [Biotech Law Review].
5. Court filings and case updates, PACER.